Tecovirimat
Antiviral medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Tecovirimat?
Summarize this article for a 10 year old
Tecovirimat, sold under the brand name Tpoxx among others,[6] is an antiviral medication with activity against orthopoxviruses such as smallpox and mpox.[4][7][8] In 2018 it became the first antipoxviral drug approved in the United States.[9][10]
Clinical data | |
---|---|
Trade names | Tpoxx |
Other names | ST-246 |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | By mouth, intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H15F3N2O3 |
Molar mass | 376.335 g·mol−1 |
3D model (JSmol) | |
| |
|
The drug works by blocking cellular transmission of the virus, thus preventing the disease.[11] It is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein.[4]
Tecovirimat has been effective in laboratory testing; it has been shown to protect animals from mpox and rabbitpox and causes no serious side effects in humans.[6] Tecovirimat was first used for treatment in December 2018, after a laboratory-acquired vaccinia virus infection.[12]
Two million doses of tecovirimat are stockpiled in the US Strategic National Stockpile should an orthopoxvirus-based bioterror attack occur.[13][14] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[15]